Latest
Response Patterns After Multiple Lines of Therapy in Mantle Cell Lymphoma
Relapse Predictors in Immune Thrombotic Thrombocytopenic Purpura After Rituximab Treatment
EULAR Recommendations for Management of Henoch-Schönlein Purpura
Safety of Allogeneic HSCT for Patients With Hepatitis-Associated Aplastic Anemia
Identifying Risk Factors for Second Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia
Ibrutinib Added to R-CHOP May Improve Outcomes for Patients Younger Than 60 Years
Subcutaneous Daratumumab Associated With Higher Patient Satisfaction, Drastically Fewer Infusion Reactions Than Intravenous Formulations
Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-Mutated Refractory AML
Heterozygous FXII Deficiency Appears Unrelated to the Incidence of Thrombotic Events
Lenalidomide Shown to Reduce the Risk of Progression in Smoldering Multiple Myeloma
Number of Hematologic Complications of Immune Checkpoint Inhibitors Appears to Be Increasing
Low Response Rates to Hypomethylating Agents in Chronic Myelomonocytic Leukemia
Featured Content
The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Novel Postremission Therapeutic Agents for Patients With Acute Myeloid Leukemia
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
High-Throughput Sequencing May Improve Diagnosis of Inherited Bleeding Disorders
Currently, molecular testing occurs at the tail end of the diagnostic workflow for inherited bleeding disorders.
Evaluating Factor Replacement Therapies for von Willebrand Disease
Variation in disease phenotype and clinical circumstances makes it difficult to create a standardized treatment approach to von Willebrand disease.
